Drug Approval | December 28, 2021
Strides to market molnupiravir under the brand name Stripiravir
Molnupiravir is an orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS-CoV-2
Molnupiravir is an orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS-CoV-2
Strides Pharma Science has reported consolidated financial results for the period ended September 30, 2021
The company expects revenue growth of 10-15 per cent in the US
The proposed acquisition will further bolster Strides US presence through acquisition of a multi dosage facility in the US.
The company has now received the renewed GMP (Good Manufacturing Practices) certificate thereby confirming the successful closure of the inspection
Mucormycosis drug AmphoTLC will be imported from Taiwan by Stelis Biopharma Private Limited (Stelis), the biotech arm of Strides group, and will be launched and distributed in India immediately by Strides
Strides Pharma Science reported total income of Rs.3367.29 crores during FY 2020-21
Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases
Element5’s Agentic AI platform will be integrated with the HCHB EHR
The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results
Subscribe To Our Newsletter & Stay Updated
